| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H27ClO7 |
| Molecular Weight | 450.909 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC=C(O[C@H]4CCOC4)C=C3)=C(Cl)C=C2
InChI
InChIKey=OBWASQILIWPZMG-QZMOQZSNSA-N
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
| Molecular Formula | C23H27ClO7 |
| Molecular Weight | 450.909 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor designed for the treatment of type 2 diabetes mellitus. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Empagliflozin interacts with diuretics, blood presure medicine and insulin. Jardiance reduces the risk of cardiovascular death in diabetes patients at high cardiovascular risk.
Originator
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Sourcing
PubMed
Sample Use Guides
The recommended dose of JARDIANCE is 10 mg once daily in the morning, taken with or without food. In patients tolerating JARDIANCE, the dose may be increased to 25 mg
In patients with volume depletion, correcting this condition prior to initiation of JARDIANCE is recommended. Assessment of renal function is recommended prior to initiation of JARDIANCE and periodically thereafter.
JARDIANCE should not be initiated in patients with an eGFR less than 45 mL/min/1.73 m^2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 mL/min/1.73 m^2. JARDIANCE should be discontinued if eGFR is persistently less than 45 mL/min/1.73 m^2.
Route of Administration:
Oral
Showing 1 to 5 of 7 entries
